Orbus Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $10M

  • Investors
  • 6

Orbus Therapeutics General Information

Description

Developer of medicinal products designed to improve the health and quality of life for patients with rare diseases. The company's products are irreversible inhibitors of ornithine decarboxylase (ODC) that delay or freeze tumor growth by inhibiting the production of the enzyme, enabling medical professionals to prevent tumor growth in certain types of cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Corporate Office
  • 2479 East Bayshore Road
  • Suite 105
  • Palo Alto, CA 94303
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Orbus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 11-Aug-2020 $10M 0000 00000 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series A3) 000 0000 0000 Completed Clinical Trials - Phase 3
2. Later Stage VC (Series A2) 20-Mar-2019 $18.5M $51M 000.00 Completed Clinical Trials - Phase 3
1. Early Stage VC (Series A) 19-Aug-2015 $32.5M $32.5M 000.00 Completed Clinical Trials - Phase 3
To view Orbus Therapeutics’s complete valuation and funding history, request access »

Orbus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-4 00,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-3 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 26,452,884 $0.010000 $1.01 $1.01 1x $1.01 31.5%
Series A 21,428,577 $0.010000 $0.84 $0.84 1x $0.84 25.52%
To view Orbus Therapeutics’s complete cap table history, request access »

Orbus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medicinal products designed to improve the health and quality of life for patients with rare diseases. The
Drug Discovery
Palo Alto, CA
9 As of 2017
0000
00000 0000-00-00
00000000000 0000

000000

equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000 000000000
Houston, TX
0 As of 0000
000.00
000.00 0000-00-00
00000000000 000.00

000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Orbus Therapeutics Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Memgen Venture Capital-Backed Houston, TX 0 000.00 00000000000 000.00
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Iovance Biotherapeutics Corporation San Carlos, CA 000 00000 00000000 00000
Galera Therapeutics Formerly VC-backed Malvern, PA 00 00000 00000000 00000
Treos Bio Venture Capital-Backed London, United Kingdom 00 000.00 0000000000 0 000.00
You’re viewing 5 of 45 competitors. Get the full list »

Orbus Therapeutics Patents

Orbus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3038530-A1 Formulations for administration of eflornithine Pending 06-Oct-2016 0000000000
EP-3523274-A4 Formulations for administration of eflornithine Pending 06-Oct-2016 0000000000 0
EP-3523274-A1 Formulations for administration of eflornithine Pending 06-Oct-2016 0000000000
AU-2017339781-B2 Formulations for administration of eflornithine Active 06-Oct-2016 000000000 0
AU-2017339781-A1 Formulations for administration of eflornithine Active 06-Oct-2016 A61K31/197
To view Orbus Therapeutics’s complete patent history, request access »

Orbus Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Robert Myers Co-Founder, President, Chief Executive Officer & Board Member
Victor Levin Co-Founder and Medical Advisor
Jason Levin Co-Founder, Board Member & Chief Operating Officer
To view Orbus Therapeutics’s complete executive team members history, request access »

Orbus Therapeutics Board Members (9)

Name Representing Role Since
Alex Zisson H.I.G. BioHealth Partners Board Member 000 0000
Ernest Mario Ph.D Self Chairman 000 0000
Geeta Vemuri Ph.D Agent Capital Board Observer 000 0000
Jason Levin Orbus Therapeutics Co-Founder, Board Member & Chief Operating Officer 000 0000
Kurt von Emster Abingworth Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Orbus Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orbus Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Venture Capital Minority 000 0000 000000 0
Agent Capital Venture Capital Minority 000 0000 000000 0
Adams Street Partners PE/Buyout Minority 000 0000 000000 0
Ernest Mario Angel (individual) Minority 000 0000 000000 0
H.I.G. BioHealth Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Orbus Therapeutics FAQs

  • When was Orbus Therapeutics founded?

    Orbus Therapeutics was founded in 2012.

  • Who is the founder of Orbus Therapeutics?

    Robert Myers, Victor Levin, and Jason Levin are the founders of Orbus Therapeutics.

  • Who is the CEO of Orbus Therapeutics?

    Robert Myers is the CEO of Orbus Therapeutics.

  • Where is Orbus Therapeutics headquartered?

    Orbus Therapeutics is headquartered in Palo Alto, CA.

  • What is the size of Orbus Therapeutics?

    Orbus Therapeutics has 9 total employees.

  • What industry is Orbus Therapeutics in?

    Orbus Therapeutics’s primary industry is Drug Discovery.

  • Is Orbus Therapeutics a private or public company?

    Orbus Therapeutics is a Private company.

  • What is the current valuation of Orbus Therapeutics?

    The current valuation of Orbus Therapeutics is 00000.

  • What is Orbus Therapeutics’s current revenue?

    The current revenue for Orbus Therapeutics is 000000.

  • How much funding has Orbus Therapeutics raised over time?

    Orbus Therapeutics has raised $67M.

  • Who are Orbus Therapeutics’s investors?

    Abingworth, Agent Capital, Adams Street Partners, Ernest Mario, and H.I.G. BioHealth Partners are 5 of 6 investors who have invested in Orbus Therapeutics.

  • Who are Orbus Therapeutics’s competitors?

    Memgen, NexImmune, Iovance Biotherapeutics, Galera Therapeutics, and Treos Bio are some of the 45 competitors of Orbus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »